Ligon Discovery
- Company typePrivate
- Founded2007
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Ligon Discovery firmographics
Firmographics- Name
- Ligon Discovery
- Website
- https://ligondiscovery.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Ligon Discovery industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Ligon Discovery is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Ligon Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Ligon Discovery product offering
Product offeringCore offering
Ligon Discovery identifies drug candidates in the fields of oncology and coagulation disorders using proprietary small molecule microarray screening technology. The company screens chemical libraries against biological targets to discover chemical probes and therapeutic leads for two specific disease areas. It operates as a research-focused drug discovery organization serving the biopharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule Drug Discovery Services Drug discovery research services using small molecule microarray screening technology to identify chemical probes and therapeutic lead candidates for oncology and coagulation disorders. The service is offered to pharmaceutical and biotechnology companies seeking externalized drug discovery capabilities.
Companies that use Ligon Discovery
Customer profileIdeal customer profiles1 record
Ligon Discovery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ligon Discovery competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Software-enabled drug discovery platform combining computational chemistry with experimental screening. Comparable to Ligon in using advanced screening/design tools to identify small molecule leads for pharma partners.
- Evotec: Global CRO and drug discovery platform offering high-throughput screening, medicinal chemistry, and integrated discovery services. Comparable as a broadly capable small molecule discovery and screening partner.
- WuXi AppTec: Large CRO/CDMO offering high-throughput screening, biology, and chemistry services for drug discovery. Comparable to Ligon in providing small molecule screening infrastructure to biotech and pharma.
- Eurofins Discovery: Discovery services arm of Eurofins providing in vitro screening, ADME, and drug discovery services. Comparable as a commercial screening service provider for early-stage small molecule discovery.
- Array BioPharma (Pfizer): Acquired by Pfizer, focused on discovery and development of small molecule drugs for oncology; established platform for kinase inhibitor discovery. Comparable as an oncology-focused small molecule discovery peer.
Direct peers
- Syros Pharmaceuticals: Small molecule drug discovery company focused on oncology using gene expression-based screening. Comparable to Ligon in employing specialized screening to identify oncology-targeted small molecules.
- Revolution Medicines: Oncology-focused small molecule discovery company targeting difficult targets including protein–protein interactions. Comparable to Ligon in tackling oncology with specialized small molecule screening approaches.
Emerging players
- Carmot Therapeutics: Small molecule discovery using chemotype-based screening and a proprietary platform to identify novel therapeutics. Comparable to Ligon in being a platform-based small molecule discovery company.
- SomaLogic: Uses a proprietary affinity-based screening platform (SOMAscan) to profile proteins and identify binders. Comparable to Ligon in applying an array-based screening technology to discover molecular interactions with biological relevance.
- Atreca: Uses high-throughput immune profiling to identify antibodies and small molecules for oncology. Comparable to Ligon in applying novel screening methodologies to oncology drug discovery.
Market position
Customer concentration
Ligon Discovery social profiles
Digital presenceLigon Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ligon Discovery leadership team
Management profileNumber of profiles
Profiles2 records
Ligon Discovery funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ligon Discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ligon Discovery
What does Ligon Discovery do?
Ligon Discovery identifies drug candidates in the fields of oncology and coagulation disorders using proprietary small molecule microarray screening technology. The company screens chemical libraries against biological targets to discover chemical probes and therapeutic leads for two specific disease areas. It operates as a research-focused drug discovery organization serving the biopharmaceutical industry.
Is Ligon Discovery a public or private company?
Ligon Discovery is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ligon Discovery founded?
Ligon Discovery was founded in 2007. It employs 1 to 10 people.
Where is Ligon Discovery based?
Ligon Discovery is headquartered in Cambridge, United States, in the North America region.
Who are Ligon Discovery's main competitors?
Broad incumbents on record are Schrödinger, Evotec, WuXi AppTec, Eurofins Discovery and Array BioPharma (Pfizer). Direct peers are Syros Pharmaceuticals and Revolution Medicines. Emerging players are Carmot Therapeutics, SomaLogic and Atreca.
Does Ligon Discovery have an API?
No public API is recorded for Ligon Discovery.
What industry is Ligon Discovery in?
Ligon Discovery's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.